Skip to content

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Menu

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Shareholders

Financial Reports

Delisting from ASX Official List

February 26, 2021

Appendix 4C – quarterly

February 1, 2021

Analyst Reports

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

July 27, 2022

Biotech Daily May 2019 – Dr Boreham's Crucible

June 13, 2019

Announcements

Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean

September 23, 2024

Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology

March 5, 2024

Invitrocue - Contact Us

Are you interested in Invitrocue?
Get in touch with our team.

All enquiries are welcome. We look forward to hearing from you!

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com

SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2024 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings